Abstract
Interactions between Eph receptor tyrosine kinases (RTKs) and membrane-anchored ephrin ligands critically regulate axon pathfinding and development of the cardiovascular system, as well as migration of neural cells. Similar to other RTKs, ligand-activated Eph kinases recruit multiple signalling and adaptor proteins, several of which are involved in growth regulation1,2. However, in contrast to other RTKs, activation of Eph receptors fails to promote cell proliferation3,4 or to transform rodent fibroblasts5, indicating that Eph kinases may initiate signalling pathways that are distinct from those transmitted by other RTKs. Here we show that stimulation of endogenous EphA kinases with ephrin-A1 potently inhibits the Ras/MAPK cascade in a range of cell types, and attenuates activation of mitogen-activated protein kinase (MAPK) by receptors for platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF). In prostatic epithelial cells and endothelial cells, but not fibroblasts, treatment with ephrin-A1 inhibits cell proliferation. Our results identify EphA kinases as negative regulators of the Ras/MAPK pathway that exert anti-mitogenic functions in a cell-type-specific manner.
Similar content being viewed by others
References
Bruckner, K. & Klein, R. Curr. Opin. Neurobiol. 8, 375–382 (1998).
Wilkinson, D. G. Int. Rev. Cytol. 196, 177–244 (2000).
Bruce, V., Olivieri, G., Eickelberg, O. & Miescher, G. C. Brain Res. 821, 169–176 (1999).
Brambilla, R. et al. EMBO J. 14, 3116–3126 (1995).
Lhotak, V. & Pawson, T. Mol. Cell. Biol. 13, 7071–7079 (1993).
Gale, N. W. et al. Neuron 17, 9–19 (1996).
Marshall, C. J. Cell 80, 179–185 (1995).
Peehl, D. M., Wong, S. T., Sellers, R. G., Jin, S. & Rhim, J. S. Carcinogenesis 18, 1643–1650 (1997).
Keyse, S. M. Curr. Opin. Cell Biol. 12, 186–192 (2000).
Brondello, J. M., Pouyssegur, J. & McKenzie, F. R. Science 286, 2514–2517 (1999).
Posern, G., Weber, C. K., Rapp, U. R. & Feller, S. M. J. Biol. Chem. 273, 24297–24300 (1998).
Walker-Daniels, J. et al. Prostate 41, 275–280 (1999).
Holland, S. J. et al. EMBO J. 16, 3877–3888 (1997).
Hock, B. et al. Oncogene 17, 255–260 (1998).
Zisch, A. H. et al. Oncogene 19, 177–187 (2000).
Anderson, D. et al. Science 250, 979–982 (1990).
Stein, E., Huynh-Do, U., Lane, A. A., Cerretti, D. P. & Daniel, T. O. J. Biol. Chem. 273, 1303–1308 (1998).
Schlessinger, J. Cell 103, 211–225 (2000).
Lindberg, R. A. & Hunter, T. Mol. Cell. Biol. 10, 6316–6324 (1990).
Gale, N. W. & Yancopoulos, G. D. Cell Tissue Res. 290, 227–241 (1997).
Miao, H., Burnett, E., Kinch, M. S., Simon, E. & Wang, B. Nature Cell Biol. 2, 62–69 (2000).
Klemke, R. L. et al. 137, 481–492 (1997).
Lee, M. S. et al. Oncogene 8, 387–393 (1993).
Peehl, D. M. in Culture of Epithelial Cells (ed. Freshney, R. I.) 159–180 (Wiley-Liss, New York,1992).
Acknowledgements
B.W. is supported by an award from CaP CURE and by grants from Department of the Army, the National Institutes of Health, and the American Heart Association. D.M.P. is supported by an award from CaP CURE.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miao, H., Wei, BR., Peehl, D. et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3, 527–530 (2001). https://doi.org/10.1038/35074604
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/35074604
- Springer Nature Limited
This article is cited by
-
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Journal of Molecular Medicine (2024)
-
Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury
Journal of Neuroinflammation (2023)
-
Targeting CDK1 in cancer: mechanisms and implications
npj Precision Oncology (2023)
-
A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor
Journal of Molecular Modeling (2023)
-
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Journal of Cancer Research and Clinical Oncology (2023)